← Back to Search

Screening for Youth Substance Use

N/A
Waitlist Available
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up in past 6 months, at 1 and 2 years post-intervention
Awards & highlights
No Placebo-Only Group

Summary

This trial found that SBIRT was effective in reducing AOD use among adolescents.

Who is the study for?
This trial is for adolescent primary care providers and their patients aged 12-18 at a specific pediatric clinic. It aims to assess methods to reduce youth alcohol and drug use. Providers outside this clinic or patient records not from this site are excluded.
What is being tested?
The study is testing two approaches of Screening, Brief Intervention, and Referral to Treatment (SBIRT) in a pediatrics clinic setting to see which is more effective at reducing alcohol and other drug use among adolescents.
What are the potential side effects?
Since the interventions involve screening and behavioral strategies rather than medications, there are no direct physical side effects like those associated with drugs; however, there may be psychological impacts due to discussing substance use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~use in past 6 months, at 1 and 2 years post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and use in past 6 months, at 1 and 2 years post-intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessment rate
Brief Intervention rate
Problem Identification rate
+2 more
Secondary study objectives
Alcohol and other drug use
Specialty Behavioral Health Treatment Initiation
Substance Use-related outcomes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Primary Care PhysicianExperimental Treatment1 Intervention
If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
Group II: Behavioral Medicine SpecialistExperimental Treatment1 Intervention
If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
Group III: Usual CareActive Control1 Intervention
Care is administered as usual
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Primary Care Physician
2017
N/A
~150

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
556 Previous Clinical Trials
27,723,652 Total Patients Enrolled

Media Library

Primary Care Physician Clinical Trial Eligibility Overview. Trial Name: NCT02408952 — N/A
Addiction Research Study Groups: Primary Care Physician, Usual Care, Behavioral Medicine Specialist
Addiction Clinical Trial 2023: Primary Care Physician Highlights & Side Effects. Trial Name: NCT02408952 — N/A
Primary Care Physician 2023 Treatment Timeline for Medical Study. Trial Name: NCT02408952 — N/A
~641 spots leftby Dec 2025